Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evorpacept + Cetuximab + Pembrolizumab in Refractory MSS mCRC
NCT05167409Phase 2Terminated
- Sponsor
- University of Colorado Denver
- Start
- Jul 2022
- Primary completion
- Oct 2024
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of evorpacept in colorectal cancer (CRC), sponsored by University of Colorado Denver. Started Jul 2022; status: terminated.
02
Drugs
evorpacept
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05167409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05167409.